Syncona Share Price (SYNC)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -0.79% 251.50 241,410 13:02:00
Bid Price Offer Price High Price Low Price Open Price
250.50 251.50 253.00 245.00 253.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 35.71 7.46 1.13 222.6 1,669
Last Trade Time Trade Type Trade Size Trade Price Currency
13:08:10 AT 961 251.50 GBX
Related Shares
Scottish Mortgage Invest... (SMT), M&g (MNG), Auctus Growth (AUCT), Energiser Investments (ENGI)

Syncona (SYNC) Latest News

Syncona News

Date Time Source Headline
1/28/20218:24IHNWFeaturedAmerican Green (OTC:ERBB) Hires Gierczyk Inc. To Design and Build the Company's New Cannabis Grow Management Operations
06/1/202109:30ALNCSyncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
06/1/202107:00UKREGSyncona Limited Autolus Business Outlook
21/12/202015:43ALNCUK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
21/12/202007:00UKREGSyncona Limited Virginia Holmes Appointed Non-Executive Director
14/12/202012:05UKREGSyncona Limited Freeline reports updated clinical data
07/12/202017:19ALNCIN BRIEF, Syncona Notes Positive Data On Autolus's Therapy Candidates
07/12/202017:05UKREGSyncona Limited Autolus presents additional data on AUTO3
07/12/202007:05UKREGSyncona Limited Autolus presents additional data on AUTO1
27/11/202016:35UKREGSyncona Limited Price Monitoring Extension
19/11/202010:12ALNCSyncona Portfolio Companies Boost Interim Result; Launches New Company
More Syncona News
Syncona Investors    Syncona Takeover Rumours

Syncona (SYNC) Discussions and Chat

Syncona Forums and Chat

Date Time Title Posts
17/12/202016:15Wellcome to Syncona569
02/5/202022:59Synchronica - Major management change heralds new strategy2
28/1/201702:52Welcome to Syncona 2
20/12/201615:28Synchronica - Mobile Technology - 20124,755
08/3/201200:18Synchronica SYNC - Mobile Phone Technology - 20113,347

Add a New Thread

Syncona (SYNC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:08:10251.509612,416.92AT
12:54:45251.612,3005,786.94O
12:34:56250.2414,00035,033.60O
12:34:31250.254041,011.03O
12:29:49250.257501,876.91O
View all Syncona trades in real-time

Syncona (SYNC) Top Chat Posts

DateSubject
28/1/2021
08:20		Syncona Daily Update: Syncona Limited is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 253.50p.
Syncona Limited has a 4 week average price of 245p and a 12 week average price of 236p.
The 1 year high share price is 280p while the 1 year low share price is currently 180p.
There are currently 663,665,537 shares in issue and the average daily traded volume is 472,602 shares. The market capitalisation of Syncona Limited is £1,669,118,825.56.
Read Full Thread
Reply
17/12/2020
16:15		chessman2: A remarkable number of buys of 1 and 2 shares today. I wonder why? Perhaps that's the reason the share price has improved so much. I'd buy in small amounts like that if the share price zoomed up but my broker charges too much. Going back to basics it is clear to me that the parts of SYNC are undervalued and that we are overdue an substantial upward appreciation.
Read Full Thread
Follow
Reply
17/12/2020
15:08		luxaeterna1: True, Freeline has raised significantly over the last two months, after the latest Phase 2 data and news of Phase 3 in 2021. NASDAQ Freeline price went from $1.70 to $18 over the last 3 months. ~ $650m MCAP now.
Read Full Thread
Follow
Reply
07/9/2020
09:20		luxaeterna1: Hard to say, Autolus had some manufacturing challenges at the UK plant and had to modify the "open" to the "closed" process, that caused some inevitable delays & trial changes and definitely seemed to impact the price at the time. Since this time, the results have been publicly back on track. I think it's a classic volatile share & it depends what timebase you use. I mean seriously, you can optimistically say the share price has tripled since March 2020, or say it is down 25% since July 2020. Both are accurate stats.
Read Full Thread
Follow
Reply
01/7/2020
06:03		brexitplus: From The Times - mention of IPO Syncona The second wave of biotech businesses being developed by Syncona, the closed-ended investment healthcare company, continues to develop nicely (Alex Ralph writes). Freeline, which is developing gene therapies for chronic diseases, raised $80 million from institutional investors yesterday, expanding an earlier series C financing, and is considering an initial public offering in the US this year. Syncona invested $40 million in December and remains the largest shareholder, with a 60 per cent stake. The series C was backed by investors including Novo Holding, the Danish life sciences investors, and Wellington, the US investor, and increases the value of Syncona’s holding to £181.5 million. Syncona is a FTSE 250 company created in 2012 through £100 million of seed funding from the Wellcome Trust, one of the biggest charitable foundations. Its aim is to generate long-term patient capital to turn the UK’s life science research base into promising healthcare companies. It has nine companies. Last year it sold Blue Earth Diagnostics, which uses molecular imaging to pinpoint prostate cancer, to Bracco Imaging for £390.2 million and Nightstar Therapeutics, a gene therapy company, to Biogen for £663 million. This helped increase Syncona’s capital pool to £767 million at the end of its full-year in March, from £399.7 million a year earlier, to reinvest in its next wave. Analysts at Numis said this month that Freeline and Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies which raised $100 million in a series B financing last year, were “shaping up to be two of the most exciting private life science companies in the UK”. Syncona’s other listed company is Autolus, which harnesses a patient’s immune system to fight cancer and is listed on the Nasdaq index. The decline in Autolus’s share price dragged down Syncona’s net asset value to £1.25 billion at the end of March, or 185½p per share, down 13.3 per cent from £1.46 billion a year earlier. However, shares in Autolus have rebounded, as has Syncona, which is up 12.5 per cent this year. Advice Buy
Read Full Thread
Follow
Reply
11/6/2020
09:55		sev22: (Alliance News) - Syncona Ltd on Thursday reported a drop in net assets over financial 2020, blaming the performance of investee Autolus, but believes it is well situated going forward. At March 31, the life sciences investor's NAV per share stood at 185.6 pence, down 14% from 216.8p at the same point a year before. Net assets ended the period at GBP1.25 billionn compared to GBP1.46 billion a year before, a 14% drop. The investment firm said it has no intention of declaring a dividend for financial 2020. In November, Syncona said "it is no longer appropriate" for it to pay a dividend, without elaborating. The NAV total return for financial 2020 was negative 13.3%. "This was driven predominantly by a decline in Autolus' share price which outweighed the write-up of Achilles and the uplift to the value of Blue Earth on sale. We believe Autolus remains well positioned to deliver for patients and continues to have good longer-term potential," Syncona said. London-based Autolus Therapeutics PLC develops T cell therapies for cancer patients. Syncona's life science portfolio stood at GBP479.5 million at March 31, down 25% over the period. Chief Executive Martin Murphy said: "2020 was a year of good strategic progress for Syncona. We expanded the expertise in our team and added a new company to our portfolio, whilst the sales of Blue Earth and Nightstar, two companies we founded, delivered very attractive cash returns. The proceeds from these sales significantly strengthened our capital pool enabling us to make long-term funding commitments, deploying GBP206.4 million into our portfolio as our next generation of companies' scale." He continued: "Our portfolio made good progress over the year including the generation of positive clinical data. The decline in Autolus' share price has clearly impacted our financial performance in the year and whilst this is disappointing, Autolus has advanced its AUTO1 programme to a pivotal study and post period end released good data from its AUTO3 DLBCL programme. We believe Autolus has the potential to deliver next generation CAR-T therapies to patients over the long-term." Looking ahead, Murphy said the need for medicines "remains undiminished". "Our strong capital pool and the deep expertise within the team means we are well positioned to support our companies in navigating continued disruption and ensure they able to progress their business plans. Whilst life science product development is never without risk, we believe our nine companies are strongly positioned to deliver value over the long-term," he added. Shares in Syncona were down 1.5% in London on Thursday morning at 219.77 pence each. Peel Hunt re-iterated its 'Add' recommendation with a target price of 286.00.
Read Full Thread
Follow
Reply
05/2/2020
10:49		tiger blue: CM day was indeed successful. Webcast recording on SYNC website, as always DYOR but do please watch if you have more than a passing interest. These are not annual or even bi-annual events for SYNC, and there is a lot of insight and an opportunity to learn about the whole current portfolio, which certainly gave me reassurance about my holding. Positives: there will be lots of newsflow to come from Freeline, Achilles and Gyroscope over the next 12-24 months as these are scaling rapidly. I think the reason share price has responded is the focus on the platforms and manufacturing they are building, that enable new products to be rolled out quicker and more efficiently. The takeover of Spark Therapeutics by Roche for $4.3bn was referenced, the price paid was far too much for the Haemophilia candidates they have, they bought it mainly for the platform. All of Syncona’s companies have a strong focus on the manufacturing of product in reliable, closed processes. Note that the recent Autolus data showed vastly superior survival rates from the closed manufacturing process vs the open. The presentation and panel discussions showed the value of being close to the science (literally 200 yds from UCL) and the benefit of sharing ideas and experience among the companies, as well as their long term approach which the scientists & founders prefer to venture cap, who always put the exit strategy on the first page. Concerns/negatives: Not many, though Brexit could be a pain in adding extra costs for different regulations in UK/EU, and long term may require manufacturing to be set up in EU as well as UK/US. Attracting European recruits may also be harder. Autolus (my view & I still hold) - I think you have to say given the share price that the jury is out as to whether they will ever get a product to market, the data is encouraging but there are other players. Price already heavily down so only 11% of SYNC portfolio and I think Freeline will be much bigger soon, but scope for a big bounce should AUTL succeed. Share price – I wouldn’t have been brave enough but someone asked Martin Murphy about the share price and I’ll end with a direct quote from him – “We can’t manage the share price, what we can do is manage the business….in the long run we all get weighed, and I’m looking forward to being weighed, because frankly the value will come out”.
Read Full Thread
Follow
Reply
26/7/2019
08:04		luxaeterna1: The SYNC share price continues a strong trend, while the AUTL price shows weakness. Perhaps related to Woodford's holding (forced sell?) and market waiting for the Q3/Q4 CAR-T updates.
Read Full Thread
Follow
Reply
06/7/2019
07:01		tiger blue: From CITYWIRE - good summary. Syncona left with £915m cash mountain after Blue Earth sale By Michelle McGagh / 05 Jul, 2019 Syncona left with £915m cash mountain after Blue Earth sale Syncona (SYNC), the UK’s largest, stock market listed life sciences fund, is sitting on a cash pile of nearly £1 billion after last week’s decision to accept a bid for prostate cancer imaging business Blue Earth Diagnostics. The FTSE 250 investment trust will receive £337 million for its 89% stake in Blue Earth, its second largest investment, from the $450 million (£354.3 million) sale of the business to Bracco Imaging of Italy, a global leader in diagnostic imaging, plus a closing adjustment payment of $25 million. This is 10-times more than its original investment of £35.5 million when it founded the firm with academics five years ago and represents an 87% internal rate of return for Syncona. The sale is the second big deal the £1.5 billion trust has done this year after making £254 million from the sale of eye disease specialist Nightstar Therapeutics to Swiss business Biogen. The proceeds from both disposals more than double the £400 million capital pool Syncona had at 31 March to £915 million leaving the portfolio around 70% in cash. While this leaves the company with plenty to invest in new and existing portfolio businesses its risks cash drag depressing returns while the money waits to be redeployed. Freeline, which focuses on gene therapy for liver diseases, retinal gene therapy business Gyroscope, and lung cancer gene therapy company Achilles, have all benefited from investment this year and the trust has said it will step up the level of investment over coming years. It has increased its guidance on how much it plans to invest each year from £75-150 million to £100-200 million. Martin Murphy, chief executive of Syncona Investment Management, said the sale of Blue Earth ‘demonstrates the success of Syncona’s strategy to found, build, and fund innovative companies’. He said in five years the company had completed clinical development, secured its first product approval, delivered a successful commercial treatment used on 50,000 prostate cancer patients and achieved profitability. Murphy told analysts the decision to sell Blue Earth was a difficult one but that the prospect of growing competition for its main product Axumin tilted the balance towards an exit and recycling its capital. The transaction provides a ‘significant’ boost adding 10.4p to net asset value (NAV) per share of around 201p, said Syncona broker Numis Securities. The uplift would have been higher but was offset by the poor performance from its quoted holdings, notably Autolus, whose shares have halved since March after their flotation on Nasdaq, the US technology exchange, last year. Autolus is the one investment Syncona shares with Neil Woodford and its declining share price adds to the pressure on his Patient Capital (WPCT) investment trust as it struggles in the aftermath of the suspension of his main Equity Income fund. Syncona shares, which are key holdings of Witan (WTAN) and BMO Managed Portfolio Growth (BMPG), have been flat since the announcement of the Blue Earth sale on 27 June. At 220p today they stand at around 10% above NAV a much reduced premium from the 51% they traded at in March before Wellcome Trust reduced its stake and Autolus shares started to slide. Jefferies analysts Ken Rumph and Lyra Li commented: ‘The transaction is another validation to SYNC's strong investment capability and business model after Nightstar's disposal and Autolus' listing, and will bring its capital pool to £963 million (146p/share), c.72% of current NAV: cash drag a problem of success?’ Ewan Lovett-Turner of Numis said the disposal showed Syncona’s portfolio is ‘likely to be highly attractive to the major biotechnology companies, and highlights the conservative nature of its valuations’. ‘We believe that Syncona is a unique vehicle with outstanding management. Syncona’s share price has been relatively weak recently, down 11.2% since 31 March, which we believe largely reflects the weakness in Autolus,’ he said.
Read Full Thread
Follow
Reply
20/5/2019
06:06		brexitplus: Syncona founds Quell Therapeutics with GBP35 million Series A Financing -- Foundation of a new Syncona company in an emerging area of cell therapy -- Significant GBP34 million commitment from Syncona in line with its strategy of founding companies to become global leaders in life science -- Syncona will have a 69.3 per cent stake(1) in the business with a holding value of GBP8.3 million(2) London, 20 May 2019 - Syncona Ltd ("Syncona") announces the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a GBP35 million commitment in a Series A financing of which Syncona has committed GBP34.0 million with a further GBP1.0 million being contributed by UCL Technology Fund. Syncona will have a 69.3 per cent stake(1) in the business, with the first tranche of the Series A commitment of GBP8.3m paid in March 2019. Quell has been established with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases. Syncona has significant domain expertise in the T-cell field, identifying Treg cells as an area of high interest in late 2017 and seeking to found a company with the potential to be a global leader in this emerging area. As part of the process, Syncona identified key opinion leaders and unified them behind a common goal of building a company to treat conditions of immune dysfunction utilising gene-modified cells. As a result, Quell has been founded in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases from King's College London, UCL, and Hannover Medical School. The GBP35 million financing will allow the company to initiate the development of its first programme. The Syncona team will work closely with Quell as it builds out its operations and management team. Syncona Chief Executive, Martin Murphy, has been appointed Chairman, whilst Elisa Petris and Freddie Dear, Syncona Partners, will be Director and Observer on the Board, respectively. Elisa Petris, Partner of Syncona Investment Management Limited, said: "The foundation of Quell represents an exciting opportunity for Syncona to build the leading cell engineering company with the potential to develop a first-in-class therapy in an innovative field. Over the last year, we have worked to bring together a group of world-class leaders in their respective fields, developed a strategy for the business and funded the business to enable it to scale and succeed. We look forward to continuing to work in close partnership with them as we build out the company's management team and business plan to deliver their goal of becoming the leader in treating conditions of immune dysfunction utilising gene-modified cells." Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: "Quell is the tenth life science company to be founded by Syncona and clearly demonstrates our proactive model in areas of deep domain expertise. We identified an innovative area of science with the potential to deliver dramatic impact for patients and worked to build a company around it. It is an exciting addition to our cell therapy platform, where we are strategically and uniquely positioned with expertise across a range of modalities." Professor Alberto Sanchez-Fueyo of Kings College London, Founding Partner, said: "We are delighted to partner with Syncona to found Quell and are excited to work with the team to develop the next generation of engineered Treg cell therapies. The founder team has a unique cross-section of expertise, built over decades of scientific research and we believe there is a significant opportunity to develop novel therapies for the treatment of solid organ transplant and autoimmune conditions. We share Syncona's vision to bring products to patients in areas of high unmet medical need and are looking forward to the journey ahead." Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at UCL, said: "Quell brings together the expertise in clinical trials, regulatory T cell biology and gene engineering at UCL, King's College London and Hannover Medical School. It is exciting to have the backing of Syncona to develop a new class of living medicine to avoid transplant rejection and treat autoimmune diseases."
Read Full Thread
Follow
Reply
16/3/2019
09:24		robow: from Investment Trust Insider Syncona’s funds boss exits as Bacit portfolio wound down By Vicky McKeever 15 Mar, 2019 Syncona’s funds boss exits as Bacit portfolio wound down Arabella Cecil, head of fund investments at Syncona (SYNC), is leaving the top-performing life sciences investment trust after the company decided to sell most of her portfolio which was hit hard by stock market falls at the end of last year. Cecil was chief financial officer at the Battle Against Cancer Investment Trust (Bacit), an innovative fund that persuaded the fund managers in which it invested to waive their fees so the money could be donated to research into fighting the disease. At the end of 2016 it merged with Syncona Partners, the investment arm of the Wellcome Trust, to form the UK's largest listed life sciences fund with a current market value of £1.6 billion. For the past two years Syncona has used the legacy Bacit portfolio of hedge and absolute return funds as a pool of capital to finance successful investments in 10 start-up life sciences companies. These include cancer specialists Autolus and Nightstar which it helped found and float on the Nasdaq, the US technology stock exchange, last year. At the end of December, Cecil's funds portfolio stood at £282 million, alongside £130 million of cash, having generated £40 million of gains since the merger. However, according to Syncona's broker Numis Securities, it fell 8.7% in the fourth quarter as global stock markets tumbled. Although this was less than the 10.2% slide in the FTSE All-Share, it was a disappointing performance for a portfolio that sought to minimise stock market volatility and was equivalent to a £3.9 million loss. This week Syncona announced it would wind down the funds portfolio in the next three-to-six months and hold more cash and cash equivalents. Its aim was to focus on 'liquidity and capital preservation' it said. Cecil will remain with Syncona while the portfolio is run down. Syncona chief executive Martin Murphy said: 'I would like to thank our head of fund Investments, Arabella Cecil, for her great contribution to Syncona, successfully managing the fund investments as part of our strategic pool of capital to enable us to fund our vision to create global leaders in life science.' Cecil's departure will leave two senior directors from Bacit at Syncona: Thomas Henderson, the brother of fund manager James Henderson, who founded the investment trust in 2012 and who sits on its board as a non-executive director; and Jeremy Tigue, the former F&C (FCIT) fund manager who has been its chairman since launch. The plan to liquidate the old Bacit funds portfolio comes as Syncona's red-hot share prices shows signs of cooling down. Investor excitement at Syncona's apparent prowess in backing the right firms at the cutting edge of diagnostic developments has seen its shares nearly double in the past three years, rising nearly 33% last year alone to peak earlier this month at a 51% premium over net asset value (NAV). However, since 4 March, when the company revealed it would receive a £135 million windfall from the £633 sale of Nightstar to Biogen, the shares have fallen 16% or 47.5p to 247p as the premium has halved to 26% over NAV. A sale this week by Wellcome Trust of 57 million or 8.7% of Syncona shares may help set a new floor for the price. The shares were placed with institutional investors at 245p, a 5% discount to their share price on Wednesday's close. Wellcome had planned to sell 45 million shares but increased the amount it was disposing in response to investor demand, according to Numis. It made £141 million, retains a holding of 28.1% in Syncona and has undertaken not to sell any more for 180 days. .
Read Full Thread
Follow
Reply
Syncona share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210128 13:25:36